ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0490

Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in PsA: Effects on Disease Markers and Tyrosine Kinase 2‒ versus Janus Kinase 1/2/3‒mediated Pathways

Oliver FitzGerald1, Dafna Gladman2, Philip Mease3, Christopher Ritchlin4, Josef Smolen5, Lu Gao6, Sarah Hu6, Miroslawa Nowak6, Subhashis Banerjee6, Ian Catlett6 and Xiang Guo6, 1Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, 2Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 4Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, 5Medical University of Vienna, Vienna, Austria, 6Bristol Myers Squibb, Princeton, NJ

Meeting: ACR Convergence 2021

Keywords: Biomarkers, Psoriatic arthritis, tyk2

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Session Title: Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)

Session Type: Abstract Session

Session Time: 2:30PM-2:45PM

Background/Purpose: Deucravacitinib is a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action that has demonstrated efficacy in patients (pts) with psoriasis and PsA. TYK2 selectively mediates cytokine signaling restricted to specific inflammatory pathways (eg, IL-23, IL-12, and Type I interferons), whereas Janus kinase (JAK) 1/2/3 signaling is involved in broader immune responses, as well as in hematopoietic pathways and in lipid metabolism. Use of JAK1/2/3 inhibitors is associated with signature changes in laboratory variables in the blood. The current study assessed the effects of deucravacitinib on biomarkers of TYK2- vs JAK1/2/3–mediated pathways, as well as of joint disease, in patients with PsA.

Methods: A double-blind Phase 2 trial (NCT03881059) enrolled 203 pts with PsA randomized 1:1:1 to deucravacitinib 6 mg once daily (QD), 12 mg QD, or placebo (PBO).1 Levels of biomarkers of interest and lymphocyte subsets in the blood were measured by immunoassays, flow cytometry, and standard methods from baseline (BL) through Week 16.

Results: BL serum concentrations of IL-23‒driven IL-17A and IL-17‒induced β-defensin 2 and IL-19 were elevated and significantly correlated with severity of skin involvement by Psoriasis Area and Severity Index scores (ρ≥0.4; P< 0.0001). Both deucravacitinib doses, but not PBO, reduced IL-17A, β-defensin 2 (Figure 1), and IL-19 over time. Serum levels of IFN-I‒driven chemokine ligand 9 (CXCL9) and CXCL10, and Type I/II IFN-inducible proteins, either remained stable or decreased after deucravacitinib treatment vs PBO. TNF-α levels remained stable in deucravacitinib-treated pts but increased in the PBO group. At BL, the neoepitope marker of Type IV collagen degradation mediated by MMPs (C4M) was positively associated with Psoriatic Arthritis Disease Activity Score (PASDAS; ρ=0.29; P< 0.0001). BL MMP3 concentrations showed modest and positive correlations with swollen joint count (ρ=0.24; P< 0.001), PASDAS (ρ=0.21; P< 0.01), and Disease Activity Index in Psoriatic Arthritis (ρ=0.19; P< 0.01). MMP3 (Figure 1) and C4M were suppressed in deucravacitinib- but not PBO-treated pts. NK cell counts remained stable and small increases in hemoglobin were observed after treatment with deucravacitinib (Figure 2). There were no clinically meaningful changes in mean levels of serum cholesterol, creatinine, neutrophils, and platelets over time with deucravacitinib treatment.

Conclusion: Deucravacitinib suppressed biomarkers of IL-23/IL-17 and IFN-I pathways concomitant with clinical symptom improvements in deucravacitinib-treated PsA pts. Joint damage is associated with an increase in MMP3, and suppression of C4M and MMP3 by deucravacitinib suggested an improvement in extracellular matrix turnover upon TYK2 pathway inhibition. Differentiation of deucravacitinib from JAK1/2/3 inhibitors was evidenced by the lack of adverse effects of deucravacitinib on hematologic and serum chemistry variables that are known to change with JAK1/2/3 inhibitors.

Reference: 1. Mease PJ et al. Presented at the 2020 ACR Convergence, American College of Rheumatology; Nov 5-9, 2020.

Slide1_v02.jpeg”

Slide2_v02.jpeg”


Disclosures: O. FitzGerald, Novartis, 5, 6, UCB, 5, 6, Pfizer, 5, 6, BMS, 5, 6, AbbVie, 5, 6, Janssen, 5, 6, Lilly, 5, 6, Biogen, 6, Eli Lilly, 5, 6; D. Gladman, AbbVie, 2, 5, Amgen, 2, 5, Eli Lilly, 2, 5, Galapagos, 2, 5, Gilead, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5, Celgene, 2, 5, Bristol Myers Squibb, 2, 5; P. Mease, AbbVie, 2, 5, 6, Amgen, 2, 5, 6, Bristol-Myers Squibb, 2, 5, Eli Lilly, 2, 5, 6, Galapagos, 2, 5, Celgene, 2, Boehringer Ingelheim, 2, Genentech, 2, 5, 6, Janssen, 2, 5, 6, Gilead Sciences, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Sun Pharma, 2, 5, UCB Pharma, 2, 6, GSK, 2; C. Ritchlin, UCB, 2, 5, AbbVie, 2, 5, Amgen, 2, 5, Eli Lilly, 2, Pfizer, 2, Novartis, 2, Gilead, 2, Janssen, 2; J. Smolen, AbbVie, 2, 5, BMS, 2, 5, Celegene, 2, 5, Chugai, 2, 5, Gilead, 2, 5, Janssen, 2, 5, Eli Lilly, 2, 5, MSD, 2, 5, Novartis-Sandoz, 2, 5, Pfizer, 2, 5, Roche, 2, 5, Samsung, 2, 5, Sanofi, 2, 5, UCB, 2, 5; L. Gao, Bristol Myers Squibb, 3, 11; S. Hu, Bristol Myers Squibb, 3, 11; M. Nowak, Bristol Myers Squibb, 3, 11; S. Banerjee, Bristol Myers Squibb, 3, 11; I. Catlett, Bristol Myers Squibb, 3, 11; X. Guo, Bristol Myers Squibb, 3, 11.

To cite this abstract in AMA style:

FitzGerald O, Gladman D, Mease P, Ritchlin C, Smolen J, Gao L, Hu S, Nowak M, Banerjee S, Catlett I, Guo X. Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in PsA: Effects on Disease Markers and Tyrosine Kinase 2‒ versus Janus Kinase 1/2/3‒mediated Pathways [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/biomarker-changes-with-selective-tyrosine-kinase-2-inhibitor-deucravacitinib-in-psa-effects-on-disease-markers-and-tyrosine-kinase-2%e2%80%92-versus-janus-kinase-1-2-3%e2%80%92mediated-pathways/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/biomarker-changes-with-selective-tyrosine-kinase-2-inhibitor-deucravacitinib-in-psa-effects-on-disease-markers-and-tyrosine-kinase-2%e2%80%92-versus-janus-kinase-1-2-3%e2%80%92mediated-pathways/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences